A double-blind, randomized, placebo-controlled, efficacy and safety study of bazedoxifene/conjugated estrogen combinations for treatment of vasomotor symptoms associated with menopause
Latest Information Update: 22 Aug 2018
Price :
$35 *
At a glance
- Drugs Conjugated estrogens/bazedoxifene (Primary)
- Indications Hot flashes; Menopausal syndrome; Vasomotor symptoms
- Focus Registrational; Therapeutic Use
- Acronyms SMART-2
- Sponsors Wyeth
- 08 Oct 2016 Pooled post hoc analysis results of SMART-1 (NCT00675688), SMART-2 (NCT00234819), SMART-3 (NCT00238732), SMART-4 (NCT00242710), and SMART-5 (NCT00808132) presented at the 27th North American Menopause Society
- 09 Feb 2015 According to a Ligand Pharmaceuticals media release, Pfizer received EU marketing approval for DUAVIVE based on the data from this study.
- 12 Oct 2013 Pooled tolerability results presented at the 24th Annual Meeting of the North American Menopause Society.